Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. USO
6. AMD
7. TSLA
8. ACN
9. COHR
10. META

Go back to Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes
(NASDAQ: ZEAL) Delayed: 17.59 --0 (-0%)
Previous Close $17.59    52 Week High $ 
Open $1.35    52 Week Low $ 
Day High $17.59    P/E N/A 
Day Low $17.59    EPS $ 
Volume 15,962